TY - JOUR
T1 - Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma
AU - Tobinai, Kensei
AU - Watanabe, Takashi
AU - Ogura, Michinori
AU - Morishima, Yasuo
AU - Hotta, Tomomitsu
AU - Ishizawa, Kenichi
AU - Itoh, Kuniaki
AU - Okamoto, Shin Ichiro
AU - Taniwaki, Masafumi
AU - Tsukamoto, Norifumi
AU - Okumura, Hirokazu
AU - Terauchi, Takashi
AU - Nawano, Shigeru
AU - Matsusako, Masaki
AU - Matsuno, Yoshihiro
AU - Nakamura, Shigeo
AU - Mori, Shigeo
AU - Ohashi, Yasuo
AU - Hayashi, Masaki
AU - Endo, Keigo
N1 - Funding Information:
Mart?n Pablo Caporgno thanks the Spanish Ministerio de Educaci?n, Cultura y Deporte for his pre-doctoral scholarship (Ref. AP2012-3726). Financial support for this research was provided by the Spanish Ministerio de Educaci?n y Ciencia and FEDER, project CTM2011-23069 and the French National Research Agency project DIESALG (ANR-12-BIME-0001-02). The authors thank Gesti? Ambiental i Abastament S.A. Company (WWTP of Reus, Spain) for their kind collaboration.
PY - 2009
Y1 - 2009
N2 - There is no data about the efficacy and safety of radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma pretreated with rituximab-containing chemotherapy. We focused on this in a Japanese phase II study. Radioimmunotherapy with 90 Y-ibritumomab tiuxetan (11.1 and 14.8 MBq) was evaluated in patients with 100-149 × 109 and >150 × 109 platelets/L, respectively. The primary endpoint was the overall response rate. Forty patients were treated with 90Y-ibritumomab tiuxetan (18 with 11.1 MBq/kg and 22 with 14.8 MBq/kg). Thirty-five patients (88%) had been pretreated with rituximab, including 27 (68%) pretreated with rituximab-containing chemotherapy. The overall response rate was 83% (33/40; 95% confidence interval, 67-93%), and the complete response rate was 68% (27/40; 95% confidence interval, 51-81%). The overall response rates in patients pretreated with rituximab-containing chemotherapy and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were 83% (19/23) and 94% (17/18), respectively. The median progression-free survival time of the 40 patients who received 90Y-ibritumomab tiuxetan was 9.6 months. Toxicity was primarily hematological and mostly transient. No grade 4 non-hematological toxicity was observed. In conclusion, radioimmunotherapy with 90Y-ibritumomab tiuxetan is safe and highly effective in patients with relapsed or refractory indolent B-cell lymphoma, including those pretreated with rituximab-containing chemotherapy.
AB - There is no data about the efficacy and safety of radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma pretreated with rituximab-containing chemotherapy. We focused on this in a Japanese phase II study. Radioimmunotherapy with 90 Y-ibritumomab tiuxetan (11.1 and 14.8 MBq) was evaluated in patients with 100-149 × 109 and >150 × 109 platelets/L, respectively. The primary endpoint was the overall response rate. Forty patients were treated with 90Y-ibritumomab tiuxetan (18 with 11.1 MBq/kg and 22 with 14.8 MBq/kg). Thirty-five patients (88%) had been pretreated with rituximab, including 27 (68%) pretreated with rituximab-containing chemotherapy. The overall response rate was 83% (33/40; 95% confidence interval, 67-93%), and the complete response rate was 68% (27/40; 95% confidence interval, 51-81%). The overall response rates in patients pretreated with rituximab-containing chemotherapy and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were 83% (19/23) and 94% (17/18), respectively. The median progression-free survival time of the 40 patients who received 90Y-ibritumomab tiuxetan was 9.6 months. Toxicity was primarily hematological and mostly transient. No grade 4 non-hematological toxicity was observed. In conclusion, radioimmunotherapy with 90Y-ibritumomab tiuxetan is safe and highly effective in patients with relapsed or refractory indolent B-cell lymphoma, including those pretreated with rituximab-containing chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=58149284058&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58149284058&partnerID=8YFLogxK
U2 - 10.1111/j.1349-7006.2008.00999.x
DO - 10.1111/j.1349-7006.2008.00999.x
M3 - Article
C2 - 19018755
AN - SCOPUS:58149284058
SN - 1347-9032
VL - 100
SP - 158
EP - 164
JO - Cancer science
JF - Cancer science
IS - 1
ER -
